Overview

Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Open, multicenter, non randomized, single arm, pilot trial.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Dolutegravir
Raltegravir Potassium